Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)

NCT07475806 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT07475806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07475806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2026
Completion date
April 30, 2031
Enrollment
240 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder cancer